Compositions comprising human milk oligosaccharides for use in individuals to support brain development and / or vision development

By delivering a nutritional composition of lactose-N-fucopentose-I or A-tetrasaccharide to infants and children, the problem of the lack of effective support for brain and vision development in infants and children in the prior art is solved, and a safe and economical development promotion effect is achieved.

CN121712403APending Publication Date: 2026-03-20SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480053980.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-29
Filing Date
2024-08-20
Publication Date
2026-03-20

AI Technical Summary

Technical Problem

There is a lack of effective, side-effect-free methods in the current technology to deliver fucoidylated human milk oligosaccharides (HMOs) to support brain and vision development in infants and children, especially the development of visual brain networks, and the delivery method needs to be widely accepted and reasonably priced.

Method used

Provides a nutritional composition containing lactose-N-fucopentose-I (LNFP-I) or A-tetrasaccharide, delivered orally or intravenously to infants, toddlers or children to promote brain and vision development, particularly the development of the lateral visual network.

Benefits of technology

It significantly improves brain and vision development in infants and children, including the development of the visual brain network, and its delivery method is safe, widely accepted, and affordable.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
Patent Text Reader

Abstract

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or vision development in a subject wherein: a) the fucosylated HMO is lactose-N-fucopentasaccharide-I (LNFP-I) and the subject is an infant of up to 12 months of age; and / or b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to a nutritional composition comprising at least one fucosylated human milk oligosaccharide for use in an individual to support brain development and / or visual development. In particular, the nutritional composition comprises lacto-N-fucopentaose-I (LNFP-I) or A-tetrasaccharide. The brain development and / or visual development includes development of visual brain networks, such as the lateral visual network (LVN). BACKGROUND

[0002] In recent years, there has been a growing interest in identifying potential links between human milk oligosaccharides (HMOs) and early brain development. Preliminary evidence based on animal studies has suggested that HMOs can play an important role in the central nervous system. For example, using long-term oral administration of 2’-FL to rodents, Vazquez et al. demonstrated that the treated animals exhibited significantly better learning and working memory functions (Vazquez et al., 2015, Journal of nutritional biochemistry, 26(5):455-465).

[0003] However, there is little data on the potential impact of other HMOs on brain function development during infancy and early childhood. To our knowledge, the present study is the first to determine the association of any HMO, and even more so of the fucosylated HMOs lacto-N-fucopentaose-I (LNFP-I) and A-tetrasaccharide, specifically on visual development in early life.

[0004] There is a need for nutritional compositions that can deliver such health benefits. There is a need to deliver such health benefits to individuals in a way that does not induce side effects and / or in a way that is not only easy to deliver (e.g. as a nutritional composition or during a meal) but also widely accepted by parents or healthcare professionals. There is also a need to deliver such benefits in a way that keeps such delivery affordable and accessible to most people. SUMMARY

[0005] The present inventors surprisingly found that the fucosylated HMOs lacto-N-fucopentaose-I (LNFP-I) and A-tetrasaccharide are significantly associated with brain and visual development in infants and children, and in particular, development of visual brain networks such as the lateral visual network (LVN).

[0006] Thus, in a first aspect, the present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or visual development in an individual, wherein:

[0007] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0008] b) the fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, a young child or a child, preferably an infant up to 12 months of age.

[0009] In another aspect, the present application provides a nutritional composition comprising a fucosylated HMO for use in improving brain development and / or visual development in an individual, wherein:

[0010] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0011] b) the fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, a young child or a child, preferably an infant up to 12 months of age.

[0012] In another aspect, the present application provides a method of improving brain development and / or visual development in an individual, the method comprising administering to the individual a fucosylated HMO, wherein:

[0013] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0014] b) the fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, a young child or a child, preferably an infant up to 12 months of age.

[0015] In another aspect, the present application provides a method of improving brain development and / or visual development in an individual, the method comprising administering to the individual a nutritional composition comprising a fucosylated HMO, wherein:

[0016] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0017] b) the fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, a young child or a child, preferably an infant up to 12 months of age.

[0018] In another aspect, the present application provides a fucosylated HMO for use in improving brain development and / or visual development in an individual, wherein:

[0019] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0020] b) the fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, a young child or a child, preferably an infant up to 12 months of age.

[0021] In another aspect, the present application provides a nutritional composition comprising a fucosylated HMO for use in improving brain development and / or visual development in an individual, wherein:

[0022] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0023] b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0024] In some embodiments, the improvement of brain development and / or visual development in the individual comprises or consists of an improvement of the development of the visual brain network.

[0025] In some embodiments, the improvement of brain development and / or visual development in the individual comprises or consists of promoting the lateral visual network (LVN).

[0026] Thus, in another aspect, the present application provides the use of a fucosylated HMO for promoting the lateral visual network (LVN) in an individual, wherein:

[0027] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0028] b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0029] In another aspect, the present application provides the use of a nutritional composition comprising a fucosylated HMO for promoting the lateral visual network (LVN) in an individual, wherein:

[0030] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0031] b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0032] In another aspect, the present application provides a method of promoting the lateral visual network (LVN) in an individual, the method comprising administering to the individual a fucosylated HMO, wherein:

[0033] a) the fucosylated HMO is lacto-N-fucopentaose-I (LNFP-I) and the individual is an infant up to 12 months of age; and / or

[0034] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0035] In another aspect, the present invention provides a method for promoting an individual's lateral visual network (LVN), the method comprising administering to the individual a nutrient composition comprising fucosylated HMOs, wherein:

[0036] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0037] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0038] In some implementations, the nutritional composition is infant formula, stage 1 infant formula, stage 2 or later infant formula, baby food, infant cereal composition, growing milk, fortifier, supplement, pet food or pet food supplement.

[0039] HMOs found in mammals other than humans are also called mammalian milk oligosaccharides (MMOs). An example of an MMO is α-tetrasaccharide. Some canine blood types are similar to human blood type A, which results in the presence of α-tetrasaccharide in their milk.

[0040] In some embodiments, particularly when the fucoidylated HMO is an A-tetrasaccharide, the nutritional composition is pet food or a pet food supplement, preferably, the pet is a dog.

[0041] In some embodiments, LNFP-I is present in a total amount of 25 mg / L to 5000 mg / L of the nutritional composition or in a total amount of 0.02 g / 100 g to 3.75 g / 100 g of the nutritional composition.

[0042] In some embodiments, the A-tetrasaccharide is present in a total amount of 22 mg / L to 500 mg / L, preferably 22 mg / L to 200 mg / L of the nutritional composition or 16 mg / 100g to 385 mg / 100g, preferably 16 mg / 100g to 155 mg / 100g of the nutritional composition. Attached Figure Description

[0043] Figure 1 Scatter plot of lateral visual functional network strength and LNFP-I level in breast milk under age-regressed regression. The line represents linear regression of the population. There is a significant positive association between lateral visual functional network strength and LNFP-I level in breast milk (p<0.05).

[0044] Figure 2Scatter plot of lateral visual function network strength and A-tetrasaccharide levels in breast milk under age-regressed regression. The line represents linear regression of the population. A significant positive association exists between lateral visual function network strength and A-tetrasaccharide levels in breast milk (p<0.05). Detailed Implementation

[0045] Definitions

[0046] As used herein, the following terms have the following meanings.

[0047] The term "individual" refers to an infant, toddler, or child.

[0048] The term "infant" refers to a child under 12 months of age.

[0049] The term "preschooler" refers to children aged between one and three years old, also known as toddlers.

[0050] The term "child" refers to a child aged between three and twelve years old. Preferably, the term "child" refers to a child aged between three and six years old.

[0051] The term "nutritional composition" refers to a composition that provides nutrients to an individual. This nutritional composition is typically ingested orally or intravenously. It may contain lipid or fat sources, carbohydrate sources, and / or protein sources. In one specific embodiment, the nutritional composition is a ready-to-drink composition, such as a ready-to-drink formula food.

[0052] In one specific embodiment, the nutritional composition of the present invention is a "synthetic nutritional composition". The term "synthetic nutritional composition" means a mixture obtained by chemical and / or biological means, the chemical properties of which may be the same as those of mixtures naturally present in mammalian milk (i.e., the synthetic nutritional composition is not breast milk).

[0053] As used herein, the term "infant formula" refers to a food intended specifically for the nutrition of infants during the first few months of life, and which itself meets the diverse nutritional needs of such individuals (in accordance with Article 2(c) of European Commission Directive 91 / 321 / EEC 2006 / 141 / EC of 22 December 2006 concerning infant formula and follow-up formula). It also refers to nutritional compositions intended for use in infants, and as defined in the Codex Alimentarius Commission (Codex STAN 72-1981) and for infant specialties (including foods for specific medical purposes).

[0054] The term "infant formula" encompasses both "starter infant formula" and "follow-up formula" or "follow-on formula".

[0055] Stage 2 infant formula or follow-up formula is given starting from the 6th month and includes growing milk. Infant formula constitutes the main liquid element in the gradually diversifying diet of this group.

[0056] The term "GUM" refers to a milk-based beverage that is typically fortified with vitamins and minerals and is intended for use by toddlers or children.

[0057] The term "infant food" refers to food specifically designed to provide nutrition for infants or young children during the first year of their lives.

[0058] The term "infant cereal composition" refers to food designed specifically to provide nutrition for infants or young children during the first year of life.

[0059] The term "fortifier" refers to a liquid or solid nutritional composition suitable for mixing with breast milk or infant formula.

[0060] The term "weaning period" refers to the period during which breast milk is gradually replaced by other foods in the diet of infants or young children.

[0061] "Breast milk" should be understood as the mother's breast milk, including colostrum, transitional milk, or mature milk.

[0062] "Oligosaccharides" are carbohydrate polymers containing small amounts (usually three to ten parts) of common sugars (monosaccharides).

[0063] The term "HMO" refers to human milk oligosaccharides. These carbohydrates are resistant to enzymatic hydrolysis by digestive enzymes (e.g., pancreas and / or brush border), indicating that their potential functions are not directly related to their calorific value. It has been specifically noted in the art that these carbohydrates play a crucial role in early infant and toddler development, such as the maturation of the immune system. Many different types of HMOs have been found in human milk. Each individual oligosaccharide is based on a variety of combinations of glucose, galactose, sialic acid (N-acetylneuraminic acid), fucose, and / or N-acetylglucosamine with these molecules, resulting in a large number of diverse oligosaccharides in human milk; more than 130 such structures have been identified to date. Almost all oligosaccharides have a lactose molecule at the reducing end, and the non-reducing end is occupied by sialic acid and / or fucose (if present). HMOs can be acidic (e.g., oligosaccharides containing charged sialic acid) or neutral (e.g., fucoidylated oligosaccharides). Some examples of HMOs are fucoidylated oligosaccharides, N-acetylated oligosaccharides, and / or sialylated oligosaccharides.

[0064] "Fucosylated oligosaccharides" are oligosaccharides containing fucose residues. These oligosaccharides are neutral. Some examples are LNFP-I (lactose-N-fucopentose I), A-tetrasaccharide, 2'-FL (2'-fucosyllactose), and 3-FL (3-fucosyllactose).

[0065] "Sialinated oligosaccharides" are oligosaccharides containing charged sialic acid, that is, oligosaccharides with sialic acid residues. These oligosaccharides are acidic. Some examples are 3'-SL (3'-sialyl-lactose) and 6'-SL (6'-sialyl-lactose). The terms "sialylated oligosaccharide" and "sialyl-lactose (SL)" are used interchangeably. The trisaccharide sialyl-lactose consists of lactose at the reducing end and one sialic acid residue at the non-reducing end, which, via α-2,3 binding or α-2,6 binding, produce 3'-SL and 6'-SL, respectively.

[0066] "HMO precursors" are key compounds that intervene in the production of HMOs, such as sialic acid and / or fucose.

[0067] The nutritional compositions of the present invention may be in solid form (e.g., powder) or liquid form. The amounts of various ingredients (e.g., oligosaccharides) may be expressed in g / 100g of composition on a dry weight basis when the composition is in solid form (e.g., powder), or in g / L of composition concentration when the composition refers to a liquid form (the latter also covers liquid compositions that can be obtained by reconstituted powder in a liquid (such as, for example, milk or water), such as reconstituted infant formula or stage 2 infant formula or growing milk or infant cereal products or any other formulation designed to provide nutrition for infants).

[0068] The term "prebiotic" refers to non-digestible carbohydrates that exert a beneficial effect on the host by selectively stimulating the growth and / or activity of healthy bacteria, such as bifidobacteria in the human colon (Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125:1401-12).

[0069] The structure of the "A-tetrasaccharide" is aD-GalNAc-(l-3)-[alpha-L-Fuc-(l-2)]--D-Gal-(l^4)-D-Glc

[0070] in

[0071] GalNAc = N-acetylgalactosamine

[0072] Fuc = Fucoose

[0073] Gal = Galactose

[0074] Glc = glucose

[0075] The term "brain development" refers to the hierarchical process of neural connections in the brain, such that later development depends on earlier development, which begins approximately two weeks after conception and continues into adolescence, up to 20 years later. Brain development builds upon itself, as connections eventually link together in more complex ways, enabling children to move, speak, and think in more complex ways. An example of this hierarchical process of brain development is that language development is highly dependent on sensory and perceptual development (e.g., speech discrimination). The term "brain development" includes the development of the lateral visual brain network. Any suitable methods for assessing visual development known in the art can be used in the practice of this invention.

[0076] The Mullen Scales of Early Learning (MSEL; Mullen EM. Mullen scales of early learning. AGS Circle Pines, MN, 1995) provides a standardized assessment of language, motor, and sensory abilities for all levels of development in children aged 5 years. Modified and updated versions produce age-normative t-scores, age-equivalent scores, and percentile rankings for the following five subdomains: 1) gross motor, 2) fine motor, 3) visual reception, 4) receptive language, and 5) expressive language. Scores from the fine motor, visual reception, receptive language, and expressive language domains can be aggregated to produce an early learning composite or developmental quotient. It is also common to derive verbal (receptive language age-equivalent score + expressive language age-equivalent score / chronological age * 100) and nonverbal (fine motor age-equivalent score + visual reception age-equivalent score / chronological age * 100) developmental quotients from this assessment. Depending on the child's age, the assessment takes 20 to 45 minutes.

[0077] Unless otherwise specified, all percentages are by weight.

[0078] Unless otherwise specified, all weights expressed in g / 100g of composition are dry weights.

[0079] Furthermore, in the context of this invention, the terms "comprising" or "including" do not exclude other possible elements. The compositions of this invention (including the various embodiments described herein) may comprise, consist of, or be substantially composed of the following elements: the essential elements and necessary limitations of the invention described herein, and any additional or optional ingredients, components, or limitations described herein or as required.

[0080] Any references to prior art documents in this specification should not be construed as an admission that such prior art is well-known or part of common knowledge in the field.

[0081] The invention will now be described in more detail. It should be noted that the various aspects, features, embodiments, and implementations described in this application may be compatible and / or combined in any combination thereof.

[0082] Improving brain development and / or visual development

[0083] Over the past few decades, numerous animal and clinical studies have supported a potential relationship between HMOs and host cognition and health, such as obesity and cardiovascular disease. Furthermore, associations exist between different HMOs. Overall, it is highly plausible that HMOs could be associated with infant cognitive development. The inventors were surprised to find that fucosylated HMOs LNFP-I and A-tetrasaccharides are significantly associated with brain and vision development.

[0084] Therefore, in a first aspect, the present invention provides fucoidylated human milk oligosaccharides (HMOs) for improving brain development and / or visual development in individuals, wherein:

[0085] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0086] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0087] In another aspect, the present invention provides a nutritional composition comprising fucosylated HMOs for improving brain development and / or visual development in an individual, wherein:

[0088] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0089] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0090] In another aspect, the present invention provides the use of fucoidylated human lactose oligosaccharides (HMOs) in the manufacture of medicaments for improving brain and / or visual development in individuals, wherein:

[0091] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0092] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0093] Suitablely, the medicine is a nutritional composition as described herein.

[0094] In another aspect, the present invention provides a method for improving brain development and / or visual development in an individual, the method comprising administering fucosylated HMO to the individual, wherein:

[0095] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0096] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0097] In another aspect, the present invention provides a method for improving brain development and / or visual development in an individual, the method comprising administering to the individual a nutritional composition comprising fucosylated HMOs, wherein:

[0098] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0099] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0100] In another aspect, the present invention provides fucosylated HMOs for improving brain development and / or visual development in individuals, wherein:

[0101] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0102] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0103] In another aspect, the present invention provides a nutritional composition comprising fucosylated HMOs for improving brain development and / or visual development in an individual, wherein:

[0104] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0105] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0106] In a preferred embodiment, when the fucosylated HMO is an A-tetrasaccharide, the individual is an infant, toddler, or child. In an alternative embodiment, when the fucosylated HMO is an A-tetrasaccharide, the individual is an infant up to 12 months of age. In an alternative embodiment, the fucosylated HMO is both LNFP-I and an A-tetrasaccharide, and the individual is an infant up to 12 months of age. In an alternative embodiment, the fucosylated HMO is LNFP-I, and the individual is an infant up to 12 months of age.

[0107] In some implementations, brain development and visual development are improved.

[0108] In some implementations, improvements in an individual's brain development and / or visual development include improvements in the development of or composition of the visual brain network.

[0109] In some implementations, improving an individual's brain development and / or visual development includes promoting the lateral visual network (LVN) or components thereof.

[0110] In some implementations, improvements in an individual's brain development include improvements in the development of or components of the visual brain network.

[0111] In some implementations, improving an individual's brain development includes promoting the lateral visual network (LVN) or components thereof.

[0112] In some implementations, improvements in an individual's visual development include improvements in the development of or components of the visual brain network.

[0113] In some implementations, improving an individual's visual development includes promoting the lateral visual network (LVN) or components thereof.

[0114] Therefore, in another aspect, the present invention provides the use of fucosylated HMOs for promoting the lateral visual network (LVN) of an individual, wherein:

[0115] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0116] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0117] In another aspect, the present invention provides the use of a nutritional composition comprising fucosylated HMO for promoting the lateral visual network (LVN) of an individual, wherein:

[0118] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0119] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0120] In another aspect, the present invention provides the use of fucosylated HMOs in the manufacture of medicaments for promoting the lateral visual network (LVN) of an individual, wherein:

[0121] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0122] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0123] Suitablely, the medicine is a nutritional composition as described herein.

[0124] On the other hand, the present invention provides a method for promoting an individual's lateral visual network (LVN), the method comprising administering fucosylated HMO to the individual, wherein:

[0125] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0126] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0127] In another aspect, the present invention provides a method for promoting an individual's lateral visual network (LVN), the method comprising administering to the individual a nutrient composition comprising fucosylated HMOs, wherein:

[0128] a) Fucosylated HMOs are lactose-N-fucopentose-I (LNFP-I), and the individuals are infants up to 12 months of age; and / or

[0129] b) Fucosylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler or child, preferably an infant up to 12 months of age.

[0130] In a preferred embodiment, when the fucosylated HMO is an A-tetrasaccharide, the individual is an infant (i.e., an infant of any age), a toddler, or a child. In an alternative embodiment, when the fucosylated HMO is an A-tetrasaccharide, the individual is an infant up to 12 months of age. In an alternative embodiment, the fucosylated HMO is both LNFP-I and an A-tetrasaccharide, and the individual is an infant up to 12 months of age. In an alternative embodiment, the fucosylated HMO is LNFP-I, and the individual is an infant up to 12 months of age.

[0131] Any suitable visual development assessment method known in the art can be used in the practice of this invention.

[0132] Appropriately, the Mullen Scales of Early Learning (MSEL; Mullen EM. Mullen scales of early learning. AGS Circle Pines, MN, 1995) can be used, which provides a standardized assessment of language, motor, and sensory abilities for all levels of children up to 5 years of age. The MSEL is described in more detail elsewhere in this article.

[0133] Appropriately, the Bayley Scales of Infant and Toddler Development (BSID; Bayley N. Third Edition: Technical Manual. San Antonio, TX: Harcourt Assessment 2006) can be used, which provides a standardized assessment of adaptive behavior, vision, language, motor and socio-emotional abilities for all levels of children up to 3.5 years of age.

[0134] Visual acuity is a measure of the finest detail that can be distinguished or recognized by the visual system.

[0135] The optimal method for measuring visual acuity in infants is visual evoked potential (VEP), as existing tools for children or adults are not optimally suited for infants. This method is particularly suitable for assessing visual acuity in individuals aged 0 to 2 years. VEP (also known as visual evoked response or VER) is an electrical signal generated by the occipital cortex of the brain in response to visual stimuli. It is recorded by one or more electrodes placed on the scalp corresponding to the visual cortex. Visual acuity can be estimated by recording the VEP response to patterned stimuli (such as alternating phases, black and white gratings), where the overall brightness of the target remains constant, but the spatial configuration of the pattern changes. Generally, as the size of the pattern elements decreases, the amplitude of the VEP decreases, resulting in a visual acuity threshold that can be estimated as the finest grating or the smallest examination size that produces a measurable VEP (for details on recording and scoring techniques, see Norcia, AM, 1994, Vision testing by visual evoked potential techniques, InS.J. Isenberg, ed., The eye in infancy, 2nd ed., pp. 157–173, St. Louis, MO: Mosby).

[0136] Therefore, appropriately, in the practice of the present invention, visual evoked potentials (VEPs) can be used to assess visual development (and in particular visual acuity).

[0137] Therefore, in some implementations, improvements in brain development and / or visual development include, or consist of, improvements in visual reception based on scores of the Mullen or Bailey scales.

[0138] In some implementations, improvements in visual development consist of improvements in visual reception based on scores from the Mullen or Bailey scales.

[0139] In some implementations, improvements in visual reception are based on scores on the Mullen Subscale.

[0140] In some implementations, improvements in visual reception are based on Bailey subscale scores.

[0141] Therefore, in some implementations, improvements in brain development and / or visual development include, or consist of, improvements in visual acuity based on visual evoked potentials (VEPs).

[0142] In some implementations, improvements in visual development consist of improvements in visual acuity based on visual evoked potentials (VEPs).

[0143] Improvements in brain development and / or visual development can be determined using any method known in the art, including magnetic resonance imaging (MRI) of the brain to determine the intensity of the lateral visual network. As a further example, the methods employed herein can be used (see Materials and Methods, Example 1).

[0144] Suitablely, when compared with the corresponding composition according to the invention that does not contain fucosylated HMO, the brain development and / or visual development of individuals using the fucosylated HMO or nutritional composition according to the invention is improved.

[0145] In some embodiments, LNFP-I is present in a total amount of 25 mg / L to 5000 mg / L of the composition or nutritional composition according to the invention, or in a total amount of 0.02 g / 100 g to 4 g / 100 g of the composition or nutritional composition according to the invention. Suitably, LNFP-I is present in a total amount of 50 mg / L to 2500 mg / L, for example 60 mg / L to 2000 mg / L, for example 80 mg / L to 1000 mg / L of the composition or nutritional composition according to the invention. Suitably, LNFP-I is present in a total amount of 0.04 g / 100 g to 2 g / 100 g, for example 0.05 g / 100 g to 1.6 g / 100 g, for example 0.07 g / 100 g to 0.8 g / 100 g of the composition or nutritional composition (dry weight).

[0146] In some embodiments, the A-tetrasaccharide is present in a total amount of 22 mg / L to 500 mg / L, preferably 22 mg / L to 200 mg / L of the nutritional composition, or 16 mg / 100g to 385 mg / 100g, preferably 16 mg / 100g to 155 mg / 100g of the nutritional composition. Suitably, the A-tetrasaccharide is present in a total amount of 22 mg / L to 400 mg / L, for example 30 mg / L to 300 mg / L, for example 40 mg / L to 200 mg / L of the composition or nutritional composition according to the invention. Suitably, the A-tetrasaccharide is present in a total amount of 16 mg / 100g to 310 mg / 100g, for example 23 mg / 100g to 235 mg / 100g, for example 30 mg / 100g to 155 mg / 100g of the composition or nutritional composition (dry weight).

[0147] Individual

[0148] When the fucosylated HMO is LNFP-I, the individual is an infant up to 12 months of age.

[0149] When the fucoidylated HMO is an A-tetrasaccharide, the individual can be an infant, toddler, or child. In one embodiment, the individual is an infant. In one embodiment, the individual is a toddler. In one embodiment, the individual is a child. In a preferred embodiment, the individual is an infant up to 12 months of age.

[0150] In other embodiments, the individual is a young animal, preferably a pet. The pet can be an animal selected from dogs, cats, birds, fish, rodents (such as mice, rats, and guinea pigs), rabbits, etc. In some embodiments, the pet is a small dog breed.

[0151] The term "juvenile" can refer to an individual who has not yet reached adulthood.

[0152] The nutritional composition or fucoidylated HMO according to the present invention can also be used in individuals born by cesarean section or vaginally.

[0153] In some embodiments, the nutritional composition or fucoidylated HMO according to the invention may be used before and / or during weaning.

[0154] In some embodiments, the nutritional composition or fucosylated HMO according to the invention is used for individuals at risk and / or in need.

[0155] Individuals at risk and / or in need may be bottle-fed and / or formula-fed. Individuals at risk and / or in need may have difficulties with visual reception and / or visual acuity. Suitablely, individuals with difficulties with visual reception and / or visual acuity may be identified using the methods described herein for assessing visual reception and visual acuity, such as the Mullen Scale for Early Learning, the Bayley Scale for Infant and Toddler Development, or visual evoked potentials.

[0156] In one embodiment, the composition or fucoidylated HMO according to the invention is given to an individual as a supplementary composition to breast milk. In some embodiments, the individual is breastfed for at least the first 2 weeks, the first 1 month, 2 months, 4 months, 6 months, or 12 months of age. In one embodiment, the nutritional composition or fucoidylated HMO according to the invention is given to the individual after the period of nutrition provided by breast milk, or given to the individual along with breast milk during the period of nutrition provided by breast milk. In another embodiment, the composition or fucoidylated HMO according to the invention is given to the individual as the sole or primary nutritional composition for at least a period of time (e.g., after the first, second, or fourth month of life), for at least 1 month, 2 months, 4 months, 6 months, or 12 months of age. In one embodiment, the nutritional composition of the invention is a complete nutritional composition (meeting all or most of the individual's nutritional needs). In another embodiment, the nutritional composition or fucoidylated HMO according to the invention is a supplement or fortifier intended for use, for example, supplementing human milk or supplementing infant formula or follow-up formula.

[0157] Other ingredients

[0158] The nutritional compositions according to the invention may also contain other types of oligosaccharides, polysaccharides, and / or their fiber and / or precursors. Other oligosaccharides and / or fibers and / or their precursors may be selected from the list including: human milk oligosaccharides (HMOs), galactooligosaccharides (GOS), fructooligosaccharides (FOS), xylooligosaccharides (XOS), oligocellulose (COS), arabinoylxylan, arabinogalactan, xylan, inulin, polydextrose, β-glucan, pectin, and any combination thereof and any derivatives thereof, such as their partially hydrolyzed products. Their amounts may be between 0% by weight and 10% by weight of the composition. In one specific embodiment, the nutritional composition or combination may also contain at least one BMO (bovine milk oligosaccharide).

[0159] HMOs that may be included in the nutritional compositions or combinations according to the invention may be selected from the group consisting of: 2'-FL (2'-fucosyllactose), 3-FL (3-fucosyllactose), lactose difucotetrasaccharide (LDFT), lactose-N-fucopentose II, lactose-N-fucopentose III, lactose-N-fucopentose V, lactose-N-fucohexasaccharide, lactose-N-difucohexasaccharide I (LNDFH) I), Fucosyl lactose-N-hexasaccharide, Fucosyl lactose-N-neohexose, Difucosyl lactose-N-hexasaccharide I, Difucosyl lactose-N-neohexose II, p-lactose-N-neohexose (p-LNnH), LNT (lactose-N-tetrasaccharide), LNnT (lactose-N-neohexose), Lactose-N-hexasaccharide, Lactose-N-neohexose, p-lactose-N-hexasaccharide, p-lactose-N-neohexose, Lactose-N-octasaccharide, Lactose-N-neohexose, Iso-lactose-N-octasaccharide, p-lactose-N-octasaccharide, Lactose-N-decasaccharide, 3'-SL (3'-sialolactose), 6'-SL (6'-sialyllactose), and any combination thereof.

[0160] In some embodiments, the nutritional composition according to the invention comprises at least one additional HMO. In other embodiments, the nutritional composition according to the invention does not contain any additional HMOs. Therefore, LNFP-I and / or α-tetrasaccharide may be the only HMOs in the nutritional composition of the invention.

[0161] The nutritional compositions according to the invention typically contain a protein source. The amount of protein can be from 1.6 g / 100 kcal to 3 g / 100 kcal. In some embodiments, the amount of protein can be between 2.4 g / 100 kcal and 4 g / 100 kcal or more than 3.6 g / 100 kcal. In some other embodiments, the amount of protein can be less than 2.0 g / 100 kcal, for example, from 1.8 g / 100 kcal to 2 g / 100 kcal, or less than 1.8 g / 100 kcal.

[0162] Protein sources based on whey, casein, or mixtures thereof, or soy-based protein sources, may be used. Regarding the whey protein of interest, the protein source may be based on acidic whey or sweet whey, or mixtures thereof, and may contain any desired proportions of α-lactalbumin and β-lactoglobulin.

[0163] In some advantageous implementations, the protein source is whey-based (i.e., more than 50% of the protein comes from whey protein, such as 60% or 70%).

[0164] The protein can be whole or hydrolyzed, or a mixture of whole and hydrolyzed proteins. The term "whole" means that the major components of the protein are intact, i.e., the molecular structure is not altered, for example, at least 80% of the protein is unchanged, such as at least 85% of the protein is unchanged, preferably at least 90% of the protein is unchanged, even more preferably at least 95% of the protein is unchanged, such as at least 98% of the protein is unchanged. In one specific embodiment, 100% of the protein is unchanged.

[0165] The term "hydrolyzed" means, in the context of this invention, that a protein has been hydrolyzed or broken down into its constituent amino acids. The protein may be completely or partially hydrolyzed. For example, providing partially hydrolyzed protein (with a degree of hydrolysis between 2% and 20%) may be desirable for infants or young children considered at risk of bovine milk allergies. If a hydrolyzed protein is required, the hydrolysis process can be carried out as needed and as is known in the art. For example, whey protein hydrolysates can be prepared by enzymatic hydrolysis of whey fractions in one or more steps. If the whey fraction used as a raw material is substantially lactose-free, it has been found that the protein undergoes far less lysine blockage during the hydrolysis process. This allows the degree of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example, about 7% by weight of lysine, which significantly improves the nutritional quality of the protein source.

[0166] In one embodiment of the invention, at least 70% of the protein is hydrolyzed, preferably at least 80%, such as at least 85%, even more preferably at least 90%, such as at least 95%, and particularly, at least 98%. In one specific embodiment, 100% of the protein is hydrolyzed.

[0167] In one specific embodiment, the protein in the nutritional composition is hydrolyzed, fully hydrolyzed, or partially hydrolyzed. The degree of hydrolysis (DH) of the protein may be between 8 and 40, or between 20 and 60, or between 20 and 80, or greater than 10, 20, 40, 60, 80, or 90.

[0168] Protein components may alternatively be replaced by mixtures or synthetic amino acids.

[0169] The nutritional compositions according to the invention typically contain a carbohydrate source. This is particularly preferred when the nutritional compositions of the invention are for infant formula. In this case, any carbohydrate source commonly found in infant formula can be used, such as lactose, sucrose, saccharin, maltodextrin, starch, and mixtures thereof, but one of the preferred carbohydrate sources is lactose.

[0170] The nutritional compositions according to the invention typically contain a lipid source. This is particularly relevant when the nutritional compositions of the invention are for infant formula. In this case, the lipid source can be any lipid or fat suitable for use in infant formula. Some suitable fat sources include palm oil, structured triglyceride oil, high-oleic sunflower oil and high-oleic safflower oil, and medium-chain triglyceride oil. Essential fatty acids linoleic acid and α-linolenic acid, as well as small amounts of oils containing large amounts of pre-formed arachidonic acid and docosahexaenoic acid, such as fish oil or microbial oil, may also be added. The ratio of n-6 fatty acids to n-3 fatty acids in the fat source can be from about 5:1 to about 15:1, for example from about 8:1 to about 10:1.

[0171] The nutritional compositions of the present invention may also contain all vitamins and minerals considered essential for a daily diet and required in significant amounts. Minimum requirements for certain vitamins and minerals have been determined. Examples of minerals, vitamins, and other nutrients optionally present in the compositions of the present invention include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are typically added in salt form. The presence and amount of specific minerals and other vitamins will vary depending on the target population.

[0172] If necessary, the nutritional compositions of the present invention may contain emulsifiers and stabilizers, such as soybean, lecithin, mono- and di-citrate citrate, etc.

[0173] The nutritional composition of the present invention may also contain other substances that may have beneficial effects, such as lactoferrin, nucleotides, nucleosides, etc.

[0174] The nutritional composition of the present invention may further contain carotenoids. In some specific embodiments of the present invention, the nutritional composition of the present invention does not contain any carotenoids.

[0175] Nutritional composition

[0176] The nutritional compositions according to the present invention may be, for example, infant formula, stage 1 infant formula, follow-up or stage 2 infant formula, growing milk, baby food, infant cereal compositions, fortifiers (such as human milk fortifiers), supplements, pet food, or pet food supplements. In some specific embodiments, the compositions of the present invention are infant formula, fortifiers, or supplements intended for infants aged 4 months or 6 months. In a preferred embodiment, the nutritional compositions of the present invention are infant formula.

[0177] The fucoidylated HMO according to the present invention can be formulated, for example, as infant formula, stage 1 infant formula, stage 2 or later infant formula, growing milk, baby food, infant cereal composition, fortifier (such as human milk fortifier), supplement, pet food or pet food supplement.

[0178] In some other embodiments, the fucosylated HMO of the nutritional composition according to the invention is a fortifier. The fortifier may be a breast milk fortifier (e.g., human milk fortifier) ​​or a formula food fortifier (such as an infant formula fortifier or a follow-up formula / stage 2 infant formula fortifier).

[0179] When the nutritional composition or fucosylated HMO according to the invention is a supplement, it can be provided in unit dose form. In such cases, it is particularly useful to limit the amount of oligosaccharides according to the daily dose to be administered to an infant, toddler, or child.

[0180] Suitably, when the nutritional composition or fucosylated HMO according to the invention is a supplement, it may contain LNFP-I and / or A-tetrasaccharide, and no other additional nutrients necessary to obtain a stable composition are contained on the top layer of the excipient. Suitably, when the nutritional composition or fucosylated HMO according to the invention is a supplement, it may contain a combination of LNFP-I and / or A-tetrasaccharide with one or more further HMOs (e.g., one or more further HMOs as described herein), and no other additional nutrients necessary to obtain a stable composition are contained on the top layer of the excipient.

[0181] The nutritional composition or fucosylated HMO according to the invention may be in solid (e.g., powder), liquid, or gel form. In one specific embodiment, the nutritional composition or fucosylated HMO according to the invention is a supplement, wherein the supplement is in powder form and provided in sachets, preferably with 0.1 g / sachet to 20 g / sachet, for example 1 g / sachet to 10 g / sachet, or provided in syrup form, preferably with a total solids concentration of 5 g / 100 mL to 75 g / 100 mL (5% to 75% (w / v)). When the supplement is in powder form, it may contain a carrier. However, it is preferred that the supplement does not contain a carrier. When the supplement is in syrup form, the components are preferably dissolved or suspended in water acidified with citrate.

[0182] In one specific embodiment, the nutritional composition or fucoidylated HMO according to the present invention is a hypoallergenic composition. In another specific embodiment, the composition or fucoidylated HMO according to the present invention is a hypoallergenic nutritional composition.

[0183] The nutritional compositions or fucoidylated HMOs according to the present invention can be prepared in any suitable manner. The compositions will now be described by way of example.

[0184] For example, formulated foods (such as infant formula) can be prepared by blending protein sources, carbohydrate sources, and fat sources together in appropriate proportions. If used, an emulsifier may be added at this stage. Vitamins and minerals may be added at this stage, but they are usually added later to avoid thermal degradation. Before blending, any lipophilic vitamins, emulsifiers, etc., can be dissolved in the fat source. Water (preferably water subjected to reverse osmosis) can then be mixed in to form a liquid mixture. The water temperature is suitably between about 50°C and about 80°C to aid in the dispersion of the components. Commercially available liquefying agents can be used to form the liquid mixture.

[0185] Oligosaccharides can be added at this stage, especially when the final product is in liquid form. If the final product is in powder form, these components can also be added at this stage as needed.

[0186] Then, the liquid mixture is homogenized in, for example, in two stages.

[0187] The liquid mixture can then be heat-treated to reduce the bacterial load, for example by rapidly heating the liquid mixture to a temperature between about 80°C and about 150°C for a duration between about 5 seconds and about 5 minutes. This can be done by steam injection, autoclaving, or a heat exchanger (e.g., a plate heat exchanger).

[0188] The liquid mixture is then cooled, for example, to between approximately 60°C and approximately 85°C by rapid cooling. It is then homogenized again, for example, in two stages, between approximately 10 MPa and approximately 30 MPa in the first stage and between approximately 2 MPa and approximately 10 MPa in the second stage. The homogenized mixture can then be further cooled to add any heat-sensitive components, such as vitamins and minerals. The pH and solids content of the homogenized mixture can then be conveniently adjusted.

[0189] If the final product is a powder, the homogenized mixture is transferred to a suitable drying apparatus, such as a spray dryer or freeze dryer, and converted into a powder. The moisture content of the powder should be less than about 5% by weight. Oligosaccharides may also be added at this stage by dry mixing them alone or together with one or more other ingredients, or by blending them in the form of crystalline syrup, and by spray drying or freeze drying the mixture.

[0190] If a liquid composition is preferred, the homogenized mixture can be sterilized and then filled into a suitable container under aseptic conditions, or it can be filled into a container first and then distilled.

[0191] In another embodiment, the composition or combination of the present invention may be a supplement. The supplement may be in the form of, for example, tablets, capsules, lozenges, or liquids. When the supplement is in liquid form, it may be an aqueous solution containing 1% to 50% by weight of HMO, preferably 5% to 35% by weight of HMO, more preferably 5% to 15% by weight of HMO, such as 10% by weight of HMO. The liquid form of the supplement may be tea or fruit juice.

[0192] Supplements may also contain protective hydrophilic colloids (such as gums, proteins, modified starches), binders, film-forming agents, encapsulation agents / materials, wall / shell materials, matrix compounds, coatings, emulsifiers, surfactants, solubilizers (oils, fats, waxes, lecithin, etc.), adsorbents, carriers, fillers, co-compounds, dispersants, wetting agents, processing aids (solvents), flow agents, flavor masking agents, weighting agents, gelling agents, and gelling agents. Supplements may also contain conventional pharmaceutical additives and adjuvants, excipients, and diluents, including but not limited to: water, gelatin of any origin, plant gums, lignin sulfonates, talc, sugars, starches, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifiers, buffers, lubricants, coloring agents, wetting agents, fillers, etc.

[0193] In addition, supplements may contain organic or inorganic carrier materials suitable for oral or parenteral administration, as well as vitamins, trace minerals, and other micronutrients recommended by government agencies such as the USRDA.

[0194] The different implementations, details, and examples described above (e.g., concerning the type and amount of oligosaccharides, nutritional compositions, application, and target populations) are also applicable to all these other purposes.

[0195] Examples

[0196] The following examples illustrate some specific embodiments of the compositions according to the present invention for the stated uses. These examples are given for illustrative purposes only and should not be construed as limiting the invention, as various changes can be made thereto without departing from the spirit of the invention.

[0197] Materials and methods

[0198] Study individuals

[0199] Parents recruited for this study provided written informed consent, agreeing to their own and their infant's participation in the study. All research activities were approved by the Institutional Review Boards of the University of North Carolina at Chapel Hill and the University of Minnesota. Individuals were recruited from both universities using a site-based research registry. Additionally, local newborn daycare centers, institutional centers focused on early brain development research, local flyers, and university list servers were also used for recruitment. Inclusion criteria were: 1) birth at 37 to 42 weeks of gestational age; 2) appropriate birth weight at gestational age; and 3) no major complications related to pregnancy and delivery. Exclusion criteria include: 1) adoption; 2) detection of autism, schizophrenia, intellectual disability, or bipolar disorder (Category I); 3) birth weight less than 2 kg; 4) neonatal hypoxia (10-minute APGAR <5); 5) illness requiring hospitalization in the neonatal intensive care unit (NICU) for more than two days; 6) chromosomal abnormalities or major congenital malformations; 7) abnormal MRI findings in previous prenatal MRIs; 8) significant medical conditions or developmental delays, or significant genetic or medical conditions affecting development, growth, or cognition (including visual / hearing impairment); 9) contraindications on MRI; and 10) maternal HIV status, preeclampsia, placental abruption, and use of alcohol or prohibited drugs during pregnancy.

[0200] Finally, additional inclusion criteria for individuals included in this study were infants under 12 months of age who were exclusively / primarily breastfed during the first four months of life, defined as infants fed less than 20g or 4 teaspoons of supplemental food / fluid (water, apple juice, etc.) and non-formula foods per day.

[0201] An accelerated longitudinal design was employed, in which the initial and follow-up visits varied between individuals. At each visit, the infant underwent a non-sedated MR imaging session during natural sleep, while human milk (HM) samples were collected from the mother.

[0202] Human milk collection and analysis

[0203] At each visit, we used a medical-grade electric Medela Symphony breast pump to obtain breast tissue samples from the right breast. To ensure the composition of the breast tissue at each feeding, we extracted breast tissue samples until no more breast tissue was expressed. Whenever possible, to minimize intra-day variability in the composition of the breast tissue, we normalized the breast tissue samples to the second feeding of the day. At least 30 mL aliquots were transferred from the collection bottle to 50 mL polypropylene Falcon tubes, thoroughly mixed by vortexing, and dispensed as 1 mL and 2 mL aliquots for storage at -80°C until further use.

[0204] For HMO quantification, representative 1 mL aliquots of HMOs were transported on dry ice to Neotron Spa (Italy). After labeling with 2-aminobenzamide, HMO analysis was performed using liquid chromatography with fluorescence detection (Austin et al., AnalChim Acta. 20 June 2018; 1010:86-96; Zhang et al., NeuroImage, 2019, 185: 664-684). Eight HMOs were quantified using standard curves with real HMO standards: 2'-FL, 3-FL, 3'-SL, 6'-SL, lactose-N-tetrasaccharide (LNT), lactose-N-neotetrasaccharide (LNnT), lactose-N-fucopentose-I (LNFP-I), and A-tetrasaccharide. In the quantification of the eight HMOs, 3'-SL and 6'-SL were logarithmically transformed to ensure the normality of their distributions.

[0205] Image acquisition, pre-processing and network construction

[0206] A detailed description of individual preparation and imaging protocols can be found in Howell et al. (2019) (Howell et al., NeuroImage, 2019, 185: 891-905). In short, prior to the imaging session, the infant was wrapped in an MRI safety blanket, and caregivers followed their infants' typical bedtime routine, carefully placing earplugs into the infants' ear canals. Light was dimmed both inside the room and en route to the scanner room. Once the infant was asleep, the study coordinator or technician guided caregivers to place the infant on the scanner table. During the scan, caregivers may remain in or leave the room, but well-trained staff remained in the room. All images were acquired using a 3 Tesla (3T) Siemens MR scanner. All individuals were imaged during unsedated and natural sleep. Anatomical and rs-fMRI images were acquired, and imaging parameters are provided in supporting materials.

[0207] For each individual, rs-fMRI images were preprocessed using the FMRIB software library (FSL) (Smith et al., Neuroimage, 2004, 23 Supplement 1: S208-19), including typical preprocessing steps. Anatomical images were segmented using iBEAT V2.0 (http: / / www.ibeat.cloud) to generate brain tissue segmentation images (Dai et al., Neuroinformatics, 2013, 11: 211-225). Each voxel was labeled as gray matter, white matter, or cerebrospinal fluid. Then, the tissue segmentation images were used to register with the MNI template using the Advanced Normalization Tool (ANTS) (Avants et al., NeuroImage, 2011, 54: 2033-2044; Li et al., NeuroImage, 2014, 90: 266-279; Li et al., Medical Image Analysis, 2015.25: 22-36; Li et al., NeuroImage, 2019, 185: 906-925; and Wang et al., Volume-Based Analysis of 6-Month-Old Infant Brain MRI for Autism Biomarker Identification and Early Diagnosis. in Medical Image Computing and Computer Assisted Intervention – MICCAI 2018. Cham: Springer International Publishing). Using a deformable field, an AAL atlas with 90 regions of interest (ROIs) (Tzourio-Mazoyer et al., NeuroImage, 2002, 15: 273-289) was deformed back to individual space to extract preprocessed time-series BOLD signals for each ROI from rs-fMRI images. Subsequently, a 90x90 functional connectivity (FC) matrix reflecting the connectivity between pairs of brain regions for each individual was derived by calculating Pearson's correlation between each pair of ROIs.Network construction was employed by matching AAL maps with functional networks detected by independent component analysis (Beckmann et al., Philos Trans R Soc Lond B Biol Sci, 2005, 360:1001-13; and Tagliazucchi et al., Neuron, 2014, 82: 695-708), including the medial visual network (MVN), lateral visual network (LVN), default mode network (DMN), sensorimotor network (SMN), auditory / language processing network (AUD / LANG), and executive control network (ECN). For each network, network connectivity strength was obtained, i.e., the average correlation coefficient of all connections within a given network. In the context of early brain development, network connectivity strength has been implied as a surrogate marker of brain functional maturation. Therefore, network connectivity strength was used as a finding in our study.

[0208] Statistical analysis

[0209] All statistical analyses were performed using RStudio version 4.0.3 (The R Foundation for Statistical Computing, Vienna, Austria). Individual linear mixed-effects models with random intercepts were fitted to the statistical analyses to capture the dependence of the same individual during visits. To ensure that age did not confound the association analysis between HMO and brain functional networks (mean FC), smoothed splines were used to regress age from HMO and brain functional networks (Hastie et al., Statistical Science, 1986, 1: 297-310, 14). Both brain network strength and HMO concentration were normalized for age regressions to ensure that the two measurements were within the same range. Specifically, two statistical models were used for subsequent association analyses to provide a comprehensive understanding of the potential relationship between HMO and brain functional networks. All models were controlled for station and full-frame displacement (FD), which quantitatively estimated the degree of individual motion during imaging as adjusting covariates.

[0210] First, a linear mixed-effects model was employed across the entire age range of our cohort, using eight HMOs for each brain functional network strength. This model captures the average association and provides an overall trend of association between HMOs and each network strength. Corrections were applied for multiple comparisons of the six networks using the false discovery rate.

[0211] Secondly, one of the main assumptions of the above approach is that the association between HMOs and brain functional networks is consistent throughout the age range assessed in our study. As outlined above, developmental rate and HMO concentration differ across different cognitive abilities (Prevention, Centers for Disease Control and Prevention, CfDCaDevelopmental Milestones. 2013; available at https: / / www.cdc.gov / ncbddd / actearly / milestones / ) and postnatal age (Austin et al., Nutrients, 2016, 8: 346). Therefore, it is reasonable that the association between brain functional networks and HMOs varies across different age ranges. We employed an age-cutoff regression approach, which allows for different associations between given functional network strength and HMOs before and after a specific age to reveal these potential behavioral associations. Specifically, the starting model included all eight HMOs. For each of the eight HMOs, an age cutoff value ranging from 3 to 15 months was applied in one-month increments. When the Akaike information criterion (AIC) (Akaike et al., IEEE Transactions on Automatic Control, 1974, 19: 716-723) is used to determine that a particular HMO fits an age cutoff better than one without any age cutoff, then that specific HMOs fit the age cutoff better, allowing for different slopes before and after the age cutoff month. Conversely, HMOs without an identified age cutoff fit the entire age range. The final model with the minimum AIC is selected using backward elimination of variables. Here, since the final model has different covariates for each brain functional network (due to the different age cutoff months and the selected HMOs), no multiple comparison correction is applied.

[0212] For the association analysis between HMO and LVN, age was regressed, and the values ​​represent the distance of each point on each plot from the fitted line by age. The original unit for HMO breast milk levels is mg / L.

[0213] Example 1

[0214] In this study, the analysis included a total of 91 individuals aged between 0.3 months and 20 months, and 156 longitudinal scans were performed.

[0215] The strength of a functional network can be assessed as the strength of the interrelationships between the parts of the functional network.

[0216] The strength of the lateral visual network (LVN) was derived by calculating the Pearson correlation between each pair of regions of interest: the superior occipital gyrus, middle occipital gyrus, inferior occipital gyrus, and superior parietal gyrus. These regions of the LVN are heavily activated in tasks associated with visual reception (Bruchhage et al., Brain Struct Funct., 2020, 225: 669–681). Therefore, the benefits associated with this domain are visual reception and visual sensitivity.

[0217] The results showed a significant positive association between LNFP-1 and the lateral visual network. Figure 1 These effects can be associated with benefits of visual reception. These effects were statistically significant in infants up to 12 months of age.

[0218] The results showed a significant positive association between α-tetraglucose and the lateral visual retina in infants, toddlers, and children. Figure 2 This can be associated with the benefits of visual reception.

[0219] Vision requires adequate maturation of the relevant brain architecture for proper development; therefore, nutritional solutions that support such maturation in infants, toddlers, and children are important. This study demonstrates for the first time the link between breast milk nutrients (specifically LNFP-I and / or A-tetrasaccharides) and LVN network maturation, which is known to be activated during visual tasks. Therefore, this study provides novel nutritional interventions to promote LVN maturation, which is fundamental to visual development.

Claims

1. Fucosylated human milk oligosaccharide (HMO), wherein the fucosylated human milk oligosaccharide (HMO) is used to improve brain development and / or visual development in an individual, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

2. A nutritional composition comprising fucosylated HMOs, said nutritional composition for improving brain development and / or visual development in an individual, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

3. The fucosylated HMO for the stated purpose according to claim 1 or the nutritional composition for the stated purpose according to claim 2, wherein the improvement in the individual's brain development and / or visual development comprises or is composed of an improvement in the development of the visual brain network.

4. The fucosylated HMO for the said purpose according to claim 1 or claim 3, or the nutritional composition for the said purpose according to claim 2 or claim 3, wherein improving the brain development and / or visual development of the individual comprises promoting the lateral visual network (LVN) or being composed thereof.

5. The nutritional composition for the purpose according to any one of claims 2 to 4, wherein the nutritional composition is infant formula, stage 1 infant formula, follow-up or stage 2 infant formula, baby food, infant cereal composition, growing milk, fortifier or supplement.

6. The nutritional composition for the purpose according to any one of claims 2 to 5, wherein LNFP-I is present in a total amount of 25 mg / L to 5000 mg / L of the nutritional composition or 0.02 g / 100 g to 3.75 g / 100 g of the nutritional composition.

7. The nutritional composition for the stated purpose according to any one of claims 2 to 6, wherein the A-tetrasaccharide is present in a total amount of 22 mg / L to 500 mg / L, preferably 22 mg / L to 200 mg / L of the nutritional composition or 16 mg / 100g to 385 mg / 100g, preferably 16 mg / 100g to 155 mg / 100g of the nutritional composition.

8. Use of fucosylated HMOs to improve individual brain development and / or visual development, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

9. Use of a nutritional composition containing fucosylated HMOs for improving individual brain development and / or visual development, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

10. The use according to claim 8 or claim 9, wherein the improvement in the brain development and / or visual development of the individual comprises or is composed of the development of the visual brain network, preferably wherein the improvement in the brain development and / or visual development of the individual comprises promoting the lateral visual network (LVN) or is composed of it.

11. Uses of fucosylated HMOs to promote the lateral visual network (LVN) in individuals, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

12. Use of a nutrient composition containing fucosylated HMOs for promoting the lateral visual network (LVN) in an individual, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

13. The use according to any one of claims 9, 10 or 12, wherein the nutritional composition is infant formula, stage 1 infant formula, stage 2 or later infant formula, baby food, infant cereal composition, growing milk, fortifier or supplement.

14. A method for improving brain development and / or visual development in an individual, the method comprising administering fucosylated HMO to the individual, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

15. A method for improving brain development and / or visual development in an individual, the method comprising administering to the individual a nutritional composition comprising fucosylated HMOs, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

16. A method for promoting the lateral visual network (LVN) of an individual, the method comprising administering fucosylated HMO to the individual, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

17. A method for promoting the lateral visual network (LVN) of an individual, the method comprising administering to the individual a nutrient composition comprising fucosylated HMO, wherein: a) The fucoidylated HMO is lactose-N-fucopentose-I (LNFP-I), and the individual is an infant up to 12 months of age; and / or b) The fucoidylated HMO is an A-tetrasaccharide, wherein the individual is an infant, toddler, or child, preferably an infant up to 12 months of age.

18. The method of claim 14 or claim 15, wherein the improvement in brain development and / or visual development comprises or is composed of an improvement in the development of a visual brain network, preferably wherein the improvement in the individual's brain development and / or visual development comprises promoting or is composed of a lateral visual network (LVN).

19. The method according to any one of claims 15, 17 or 18, wherein the nutritional composition is infant formula, stage 1 infant formula, stage 2 or later infant formula, baby food, infant cereal composition, growing milk, fortifier or supplement.